Certified Specialist in Obesity and Weight Management (CSOWM) Practice Exam 2026 - Free CSOWM Practice Questions and Study Guide

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards

From $12.50Unlock all

Session length

1 / 20

Which obesity medication is a once-weekly GLP-1 receptor agonist approved for weight management?

Liraglutide (Saxenda)

Orlistat (Xenical)

Naltrexone/bupropion (Contrave)

Semaglutide (Wegovy)

Semaglutide (Wegovy) is the once-weekly GLP-1 receptor agonist approved for weight management. GLP-1 receptor agonists work by slowing gastric emptying and increasing satiety, which reduces hunger and helps people eat less. The weekly dosing makes it convenient and supports better adherence compared with daily injections. Among the options, another GLP-1 agonist, liraglutide (Saxenda), is effective but given daily, not weekly. The other choices work via different mechanisms—Orlistat blocks fat absorption, and naltrexone/bupropion targets reward pathways—so they’re not the weekly GLP-1 receptor agonist approved for weight management. Wegovy combines a weekly schedule with robust weight-loss results seen in clinical trials, making it the best fit.